All > Massachusetts Investigators

Katie Mullins

Dana-Farber Cancer Institute

Boston, Massachusetts - 02115

CLINICAL TRIALS 2
CONDITIONS10
INTERVENTIONS1
SINCE2008

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

June 2008 - September 2011

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

March 2010 - March 2012

Lymphoma

Lymphoma, Non-Hodgkin

Multiple Myeloma

Neoplasms, Plasma Cell

Leukemia

Leukemia, Lymphocytic, Chronic, B-Cell

Leukemia, Lymphoid

Leukemia, Myeloid, Acute

Leukemia, Myeloid

Hematologic Neoplasms

Cal-101

Learn about TrialX Patient Recruitment services

Massimo Loda, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

Suzanne Shusterman

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Childrens Hospital Boston, Dana-Farber Cancer Institute. Children's Hospital Boston

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute Dana Farber / Brigham and Women's Cancer Center Dana-Farber Cancer Institute, Center for Neuro-Oncology Dana-Farber Cancer Instiute

Lewis B. Silverman, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute and Children's Hospital Dana Faber Cancer Institute, Children's Hospital, Dept. of Pediatric Oncology Children's Hospital Boston Dana-Farber Cancer Institute

Katie Mullins

Dana-Farber Cancer Institute

Massimo Loda, MD

Suzanne Shusterman

Patrick Y. Wen, MD

Lewis B. Silverman, MD

Kay Kehoe, Coordinator

Jennifer Brown, MD

Rachel A. Freedman

Edwin P. Alyea, MD

F. Stephen Hodi, MD

Beth A. Overmoyer, MD, FACP